COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
3.340
-0.030 (-0.89%)
Jun 27, 2025, 4:00 PM - Market closed
COSCIENS Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 9.03 | 9.59 | 7.14 | 14.57 | 5.26 | 3.65 | Upgrade
| |
Revenue Growth (YoY) | 36.51% | 34.22% | -50.98% | 177.03% | 44.03% | 586.47% | Upgrade
|
Cost of Revenue | 4.76 | 4.86 | 4.21 | 6.02 | 0.09 | 2.32 | Upgrade
|
Gross Profit | 4.27 | 4.73 | 2.94 | 8.56 | 5.17 | 1.34 | Upgrade
|
Selling, General & Admin | 7.64 | 6.37 | 5.53 | 2.87 | 7.27 | 5.89 | Upgrade
|
Research & Development | 8.38 | 8.3 | 2.04 | 1.37 | 6.57 | 1.51 | Upgrade
|
Other Operating Expenses | - | - | - | - | - | -0.14 | Upgrade
|
Operating Expenses | 16.01 | 14.67 | 7.57 | 4.24 | 13.84 | 7.26 | Upgrade
|
Operating Income | -11.75 | -9.94 | -4.63 | 4.32 | -8.67 | -5.93 | Upgrade
|
Interest Expense | -0.14 | -0.13 | -0.14 | -0.14 | -0.01 | -0 | Upgrade
|
Interest & Investment Income | 0.49 | 0.44 | 0.06 | 0.15 | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -0.03 | 0.05 | -0.02 | 0.21 | 0.22 | 0.57 | Upgrade
|
Other Non Operating Income (Expenses) | 2.69 | 2.7 | 0.36 | -0.01 | -0.01 | 0.42 | Upgrade
|
EBT Excluding Unusual Items | -8.73 | -6.89 | -4.37 | 4.53 | -8.48 | -4.94 | Upgrade
|
Merger & Restructuring Charges | -4.08 | -4.08 | - | - | - | - | Upgrade
|
Asset Writedown | -4.26 | -4.26 | - | - | - | - | Upgrade
|
Other Unusual Items | - | - | - | - | - | 0.22 | Upgrade
|
Pretax Income | -17.07 | -15.23 | -4.37 | 4.53 | -8.48 | -4.72 | Upgrade
|
Income Tax Expense | 0.5 | 0.08 | -0.89 | 1.08 | -0.11 | 0.4 | Upgrade
|
Earnings From Continuing Operations | -17.56 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade
|
Net Income | -17.56 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade
|
Net Income to Common | -17.56 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade
|
Shares Outstanding (Basic) | 3 | 3 | 2 | 2 | 1 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 3 | 3 | 2 | 2 | 1 | 0 | Upgrade
|
Shares Change (YoY) | 57.27% | 39.74% | -0.39% | 61.37% | 179.74% | 134.83% | Upgrade
|
EPS (Basic) | -6.04 | -5.93 | -1.89 | 1.87 | -7.28 | -12.46 | Upgrade
|
EPS (Diluted) | -6.04 | -5.93 | -1.89 | 1.86 | -7.28 | -12.46 | Upgrade
|
Free Cash Flow | -15.28 | -15.73 | -3.3 | 4.93 | -8.61 | -4.13 | Upgrade
|
Free Cash Flow Per Share | -5.26 | -6.09 | -1.79 | 2.66 | -7.49 | -10.05 | Upgrade
|
Gross Margin | 47.27% | 49.33% | 41.13% | 58.71% | 98.29% | 36.55% | Upgrade
|
Operating Margin | -130.07% | -103.70% | -64.81% | 29.65% | -164.85% | -162.24% | Upgrade
|
Profit Margin | -194.50% | -159.69% | -48.79% | 23.66% | -159.09% | -140.14% | Upgrade
|
Free Cash Flow Margin | -169.21% | -164.07% | -46.26% | 33.80% | -163.71% | -113.06% | Upgrade
|
EBITDA | -10.52 | -8.68 | -3.47 | 5.79 | -8.53 | -5.69 | Upgrade
|
EBITDA Margin | -116.44% | -90.52% | -48.62% | 39.72% | -162.09% | -155.89% | Upgrade
|
D&A For EBITDA | 1.23 | 1.26 | 1.16 | 1.47 | 0.15 | 0.23 | Upgrade
|
EBIT | -11.75 | -9.94 | -4.63 | 4.32 | -8.67 | -5.93 | Upgrade
|
EBIT Margin | -130.07% | -103.70% | -64.81% | 29.65% | -164.85% | -162.24% | Upgrade
|
Effective Tax Rate | - | - | - | 23.85% | - | - | Upgrade
|
Updated Apr 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.